When do you recommend endocrine therapy for chemoprevention in women with high-risk benign breast lesions?

Women with atypical hyperplasia or lobular carcinoma in situ have a 4-10 fold increase in breast cancer risk. In the randomized controlled trials of endocrine therapy for chemoprevention for 5 years, this subset of women with high-risk benign breast lesions had up to a 60-70% relative risk reduction...